TACR1 and cancer: Table 1 shows references to 59 published studies of growth inhibition by aprepitant in 22 different cancers, indicating that NK-1 may be a pan-malignant growth element. Overall, 12 of these 59 studies demonstrated growth inhibition specifically in GB [9,25,26,27,28,29,30,31,32,33,34,35]. After reviewing several of these studies, Munoz and Russo concluded in 2025 that “...all glioma cells express NK-1R, and NK-1R is essential for the viability of glioma cells and not of normal cells” [24].